Navigation Links
MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product
Date:2/11/2008

RALEIGH, N.C., Feb. 11 /PRNewswire/ -- MedThink Communications, an innovator in medical communications, brand development, advertising and public relations, has been retained by Salix Pharmaceuticals, Inc, in Morrisville to launch and promote its newest product under development, an orally disintegrating form of metoclopramide.

Salix recently licensed the rights to market the orally disintegrating metoclopramide tablet and will bring the drug to market following approval from the Food and Drug Administration.

MedThink's team of communication professionals will initiate a branding and promotional campaign that includes logo design, an advertising campaign, promotional material and public relations strategies. The medical communications team at MedThink will educate scientific and professional audiences through peer-reviewed manuscripts, abstracts and posters.

"We felt that MedThink was the right agency to help us launch this new product because of their creativity and understanding of the gastroenterology market," said Ellen Marth McKim, vice president of marketing at Salix.

MedThink is also the agency of record for several of Salix's gastrointestinal products, including the colonoscopy preparation OsmoPrep (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) and the targeted antibiotic Xifaxan (rifaximin).

"We are thrilled to have the opportunity to expand our long-standing relationship with Salix," said Walt Clarke, partner at MedThink. "We continually strive to create lively and engaging campaigns that convey the essence of Salix's brand and its products, and we are excited to be named their partner in this latest endeavor."

ABOUT MEDTHINK COMMUNICATIONS

MedThink Communications is an award-winning, full-service agency whose communications strategies capture the essence of your brand and transform it into compelling messages that inspire your target audiences. Our innovative approach to advertising, medical communications, public relations, media planning and placement, sales training and marketing consulting serves as the perfect complement to strengthen our health care partners' competitive edge. (http://www.medthink.com)

OsmoPrep Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OsmoPrep is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, acute obstruction or pseudo-obstruction of the bowel, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of acute phosphate nephropathy, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OsmoPrep. OsmoPrep is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OsmoPrep be advised to adequately hydrate before, during, and after the use of OsmoPrep. Full prescribing information may be found at http://salix.com/assets/pdf/osmoprep/osmoprep_prescribing_info.pdf.

XIFAXAN (rifaximin) Tablets are indicated for the treatment of patients (greater than or equal to 12 years of age) with travelers' diarrhea caused by noninvasive strains of Escherichia coli. XIFAXAN should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. XIFAXAN should be discontinued if diarrhea symptoms get worse or persist more than 24-48 hours, and alternative antibiotic therapy should be considered. Escherichia coli has been shown to develop resistance to rifaximin in vitro. However, the clinical significance of such an effect has not been studied.

In clinical trials, XIFAXAN was generally well tolerated. The most common side effects (vs placebo) were flatulence 11.3% (vs 19.7%), headache 9.7% (vs 9.2%), abdominal pain 7.2% (vs 10.1%), and rectal tenesmus 7.2% (vs 8.8%). Full prescribing information may be found at http://salix.com/assets/pdf/xifaxan/XifaxanPI.pdf.


'/>"/>
SOURCE MedThink Communications
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedThink Communications Retained by NanoBio Corporation
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. National Patient Safety Foundation Partners with Vocera Communications
4. Vida Health Communications, Inc. to Be Honored as Tibbetts Award Winner
5. N. V. Perricone M.D. Cosmeceuticals Elevates Role of Christina Banas to Executive Director Global Communications
6. Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy
7. Centre De Sante et de Services Sociaux Haut-Richelieu-Rouville in Quebec Selects Alcatel-Lucent and SSP Telecom to Upgrade its Communications Infrastructure
8. AutoTrader Publishing, AutoMart.com and Cox Communications Present $500,000 Grant to the Childrens Hospital of the Kings Daughters
9. AHRQ Report Recommends Use of Existing Call Centers to Expand Communications in Public Health Emergencies
10. Telecommunications Technology Boosts Revenue Generation by Billions and Builds Positive Brand Experience
11. Enova Medical Technologies Names Wayne Ramaker Vice President of Marketing and Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: